TGFβ and EGF signaling orchestrates the AP-1- and p63 transcriptional regulation of breast cancer invasiveness.


Journal

Oncogene
ISSN: 1476-5594
Titre abrégé: Oncogene
Pays: England
ID NLM: 8711562

Informations de publication

Date de publication:
05 2020
Historique:
received: 23 09 2019
accepted: 09 04 2020
revised: 04 04 2020
pubmed: 1 5 2020
medline: 1 12 2020
entrez: 1 5 2020
Statut: ppublish

Résumé

Activator protein (AP)-1 transcription factors are essential elements of the pro-oncogenic functions of transforming growth factor-β (TGFβ)-SMAD signaling. Here we show that in multiple HER2+ and/or EGFR+ breast cancer cell lines these AP-1-dependent tumorigenic properties of TGFβ critically rely on epidermal growth factor receptor (EGFR) activation and expression of the ΔN isoform of transcriptional regulator p63. EGFR and ΔNp63 enabled and/or potentiated the activation of a subset of TGFβ-inducible invasion/migration-associated genes, e.g., ITGA2, LAMB3, and WNT7A/B, and enhanced the recruitment of SMAD2/3 to these genes. The TGFβ- and EGF-induced binding of SMAD2/3 and JUNB to these gene loci was accompanied by p63-SMAD2/3 and p63-JUNB complex formation. p63 and EGFR were also found to strongly potentiate TGFβ induction of AP-1 proteins and, in particular, FOS family members. Ectopic overexpression of FOS could counteract the decrease in TGFβ-induced gene activation after p63 depletion. p63 is also involved in the transcriptional regulation of heparin binding (HB)-EGF and EGFR genes, thereby establishing a self-amplification loop that facilitates and empowers the pro-invasive functions of TGFβ. These cooperative pro-oncogenic functions of EGFR, AP-1, p63, and TGFβ were efficiently inhibited by clinically relevant chemical inhibitors. Our findings may, therefore, be of importance for therapy of patients with breast cancers with an activated EGFR-RAS-RAF pathway.

Identifiants

pubmed: 32350443
doi: 10.1038/s41388-020-1299-z
pii: 10.1038/s41388-020-1299-z
pmc: PMC7253358
doi:

Substances chimiques

FOS protein, human 0
JUN protein, human 0
Neoplasm Proteins 0
Protein Kinase Inhibitors 0
Proto-Oncogene Proteins c-fos 0
Proto-Oncogene Proteins c-jun 0
Smad Proteins 0
TP63 protein, human 0
Transcription Factor AP-1 0
Transcription Factors 0
Transforming Growth Factor beta1 0
Tumor Suppressor Proteins 0
Epidermal Growth Factor 62229-50-9
EGFR protein, human EC 2.7.10.1
ERBB2 protein, human EC 2.7.10.1
ErbB Receptors EC 2.7.10.1
Receptor, ErbB-2 EC 2.7.10.1
Receptor, Transforming Growth Factor-beta Type I EC 2.7.11.30
TGFBR1 protein, human EC 2.7.11.30

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

4436-4449

Références

Roberts AB, Anzano MA, Lamb LC, Smith JM, Frolik CA, Marquardt H. et al. Isolation from murine sarcoma cells of novel transforming growth factors potentiated by EGF. Nature.1982;295:417–9.
pubmed: 6276769 doi: 10.1038/295417a0
Moses HL, Roberts AB, Derynck R. The discovery and early days of TGF-β: a historical perspective. Cold Spring Harb Perspect Biol. 2016;8:a021865.
pubmed: 27328871 pmcid: 4930926 doi: 10.1101/cshperspect.a021865
Lemmon MA, Schlessinger J. Cell signaling by receptor tyrosine kinases. Cell. 2010;141:1117–34.
pubmed: 20602996 pmcid: 2914105 doi: 10.1016/j.cell.2010.06.011
Massague J. TGFβ signalling in context. Nat Rev Mol Cell Biol. 2012;13:616–30.
pubmed: 22992590 pmcid: 4027049 doi: 10.1038/nrm3434
Katsuno Y, Lamouille S, Derynck R. TGF-β signaling and epithelial-mesenchymal transition in cancer progression. Curr Opin Oncol. 2013;25:76–84.
pubmed: 23197193 doi: 10.1097/CCO.0b013e32835b6371
Akhurst RJ, Padgett RW. Matters of context guide future research in TGFβ superfamily signaling. Sci Signal. 2015;8:re10.
pubmed: 26486175 doi: 10.1126/scisignal.aad0416
David CJ, Massague J. Contextual determinants of TGFβ action in development, immunity and cancer. Nat Rev Mol Cell Biol. 2018;19:419–35.
pubmed: 29643418 doi: 10.1038/s41580-018-0007-0
Wilson CA, Cajulis EE, Green JL, Olsen TM, Chung YA, Damore MA. et al. HER-2 overexpression differentially alters transforming growth factor-β responses in luminal versus mesenchymal human breast cancer cells. Breast Cancer Res. 2005;7:R1058–79.
pubmed: 16457687 pmcid: 1410754 doi: 10.1186/bcr1343
Chow A, Arteaga CL, Wang SE. When tumor suppressor TGFβ meets the HER2 (ERBB2) oncogene. J Mammary Gland Biol Neoplasia. 2011;16:81–8.
pubmed: 21590373 pmcid: 3398103 doi: 10.1007/s10911-011-9206-4
Hill CS. Transcriptional control by the SMADs. Cold Spring Harb Perspect Biol. 2016;8:pii: a022079.
pubmed: 27449814 pmcid: 5046698 doi: 10.1101/cshperspect.a022079
Derynck R, Budi EH. Specificity, versatility, and control of TGF-β family signaling. Sci Signal. 2019;12:pii: eaav5183.
pubmed: 30808818 pmcid: 6800142 doi: 10.1126/scisignal.aav5183
Ikushima H, Miyazono K. TGF-beta signal transduction spreading to a wider field: a broad variety of mechanisms for context-dependent effects of TGF-β. Cell Tissue Res. 2012;347:37–49.
pubmed: 21618142 doi: 10.1007/s00441-011-1179-5
Sundqvist A, ten Dijke P, van Dam H. Key signaling nodes in mammary gland development and cancer: Smad signal integration in epithelial cell plasticity. Breast Cancer Res. 2012;14:204.
pubmed: 22315972 pmcid: 3496114 doi: 10.1186/bcr3066
Huang F, Shi Q, Li Y, Xu L, Xu C, Chen F. et al. HER2/EGFR-AKT signaling switches TGFβ from inhibiting cell proliferation to promoting cell migration in breast cancer. Cancer Res. 2018;78:6073–85.
pubmed: 30171053 doi: 10.1158/0008-5472.CAN-18-0136
Shaulian E, Karin M. AP-1 as a regulator of cell life and death. Nat Cell Biol. 2002;4:E131–6.
pubmed: 11988758 doi: 10.1038/ncb0502-e131
Eferl R, Wagner EF. AP-1: a double-edged sword in tumorigenesis. Nat Rev Cancer. 2003;3:859–68.
pubmed: 14668816 doi: 10.1038/nrc1209
Hess J, Angel P, Schorpp-Kistner M. AP-1 subunits: quarrel and harmony among siblings. J Cell Sci. 2004;117:5965–73.
pubmed: 15564374 pmcid: 15564374 doi: 10.1242/jcs.01589
Durchdewald M, Angel P, Hess J. The transcription factor Fos: a Janus-type regulator in health and disease. Histol Histopathol. 2009;24:1451–61.
pubmed: 19760594
Lopez-Bergami P, Lau E, Ronai Z. Emerging roles of ATF2 and the dynamic AP1 network in cancer. Nat Rev Cancer. 2010;10:65–76.
pubmed: 20029425 pmcid: 2874064 doi: 10.1038/nrc2681
Shaulian E. AP-1-The Jun proteins: oncogenes or tumor suppressors in disguise? Cell Signal. 2010;22:894–9.
pubmed: 20060892 doi: 10.1016/j.cellsig.2009.12.008
Vierbuchen T, Ling E, Cowley CJ, Couch CH, Wang X, Harmin DA. et al. AP-1 transcription factors and the BAF complex mediate signal-dependent enhancer selection. Mol Cell. 2017;68:1067–82. e12.
pubmed: 29272704 pmcid: 5744881 doi: 10.1016/j.molcel.2017.11.026
Madrigal P, Alasoo K. AP-1 takes centre stage in enhancer chromatin dynamics. Trends Cell Biol. 2018;28:509–11.
pubmed: 29778529 doi: 10.1016/j.tcb.2018.04.009
Belguise K, Kersual N, Galtier F, Chalbos D. FRA-1 expression level regulates proliferation and invasiveness of breast cancer cells. Oncogene. 2005;24:1434–44.
pubmed: 15608675 doi: 10.1038/sj.onc.1208312
Ozanne BW, Spence HJ, McGarry LC, Hennigan RF. Transcription factors control invasion: AP-1 the first among equals. Oncogene. 2007;26:1–10.
pubmed: 16799638 doi: 10.1038/sj.onc.1209759
Sundqvist A, Zieba A, Vasilaki E, Herrera Hidalgo C, Soderberg O, Koinuma D. et al. Specific interactions between Smad proteins and AP-1 components determine TGFβ-induced breast cancer cell invasion. Oncogene. 2012;32:3606–15.
pubmed: 22926518 doi: 10.1038/onc.2012.370
Desmet CJ, Gallenne T, Prieur A, Reyal F, Visser NL, Wittner BS. et al. Identification of a pharmacologically tractable Fra-1/ADORA2B axis promoting breast cancer metastasis. Proc Natl Acad Sci USA. 2013;110:5139–44.
pubmed: 23483055 doi: 10.1073/pnas.1222085110
Tam WL, Lu H, Buikhuisen J, Soh BS, Lim E, Reinhardt F. et al. Protein kinase C alpha is a central signaling node and therapeutic target for breast cancer stem cells. Cancer Cell. 2013;24:347–64.
pubmed: 24029232 pmcid: 4001722 doi: 10.1016/j.ccr.2013.08.005
Dhillon AS, Tulchinsky E. FRA-1 as a driver of tumour heterogeneity: a nexus between oncogenes and embryonic signalling pathways in cancer. Oncogene. 2015;34:4421–28.
pubmed: 25381818 doi: 10.1038/onc.2014.374
Bakiri L, Macho-Maschler S, Custic I, Niemiec J, Guio-Carrion A, Hasenfuss SC. Fra-1/AP-1 induces EMT in mammary epithelial cells by modulating Zeb1/2 and TGFβ expression. Cell Death Differ. 2015;22:336–50.
pubmed: 25301070 doi: 10.1038/cdd.2014.157
Zhang Y, Feng XH, Derynck R. Smad3 and Smad4 cooperate with c-Jun/c-Fos to mediate TGF-β-induced transcription. Nature. 1998;394:909–13.
pubmed: 9732876 doi: 10.1038/29814
Koinuma D, Tsutsumi S, Kamimura N, Taniguchi H, Miyazawa K, Sunamura M. et al. Chromatin immunoprecipitation on microarray analysis of Smad2/3 binding sites reveals roles of ETS1 and TFAP2A in transforming growth factor β signaling. Mol Cell Biol. 2009;29:172–86.
pubmed: 18955504 doi: 10.1128/MCB.01038-08
Sundqvist A, Morikawa M, Ren J, Vasilaki E, Kawasaki N, Kobayashi M. et al. JUNB governs a feed-forward network of TGFβ signaling that aggravates breast cancer invasion. Nucleic Acids Res. 2018;46:1180–95.
pubmed: 29186616 doi: 10.1093/nar/gkx1190
Chen Y, Peng Y, Fan S, Li Y, Xiao ZX, Li C. A double dealing tale of p63: an oncogene or a tumor suppressor. Cell Mol Life Sci. 2018;75:965–73.
pubmed: 28975366 doi: 10.1007/s00018-017-2666-y
Gatti V, Bongiorno-Borbone L, Fierro C, Annicchiarico-Petruzzelli M, Melino G, Peschiaroli A. p63 at the crossroads between stemness and metastasis in breast cancer. Int J Mol Sci. 2019;20:pii: E2683.
pmcid: 6600246 doi: 10.3390/ijms20112683
Vasilaki E, Morikawa M, Koinuma D, Mizutani A, Hirano Y, Ehata S. et al. Ras and TGF-β signaling enhance cancer progression by promoting the DeltaNp63 transcriptional program. Sci Signal. 2016;9:ra84
pubmed: 27555661 doi: 10.1126/scisignal.aag3232
Wiercinska E, Naber HP, Pardali E, van der Pluijm G, van Dam H, ten Dijke P. The TGF-β/Smad pathway induces breast cancer cell invasion through the up-regulation of matrix metalloproteinase 2 and 9 in a spheroid invasion model system. Breast Cancer Res Treat. 2011;128:657–66.
pubmed: 20821046 doi: 10.1007/s10549-010-1147-x
Soule HD, Maloney TM, Wolman SR, Peterson Jr. WD, Brenz R, McGrath CM. et al. Isolation and characterization of a spontaneously immortalized human breast epithelial cell line, MCF-10. Cancer Res. 1990;50:6075–86.
pubmed: 1975513
Dawson PJ, Wolman SR, Tait L, Heppner GH, Miller FR. MCF10AT: a model for the evolution of cancer from proliferative breast disease. Am J Pathol. 1996;148:313–9.
pubmed: 8546221 pmcid: 1861604
Carroll DK, Carroll JS, Leong CO, Cheng F, Brown M, Mills AA. et al. p63 regulates an adhesion programme and cell survival in epithelial cells. Nat Cell Biol. 2006;8:551–61.
pubmed: 16715076 doi: 10.1038/ncb1420
Eferl R, Ricci R, Kenner L, Zenz R, David JP, Rath M. et al. Liver tumor development. c-Jun antagonizes the proapoptotic activity of p53. Cell. 2003;112:181–92.
pubmed: 12553907 doi: 10.1016/S0092-8674(03)00042-4
Gatti V, Fierro C, Compagnone M, Giangrazi F, Markert EK, Bongiorno-Borbone L. et al. ΔNp63 regulates the expression of hyaluronic acid-related genes in breast cancer cells. Oncogenesis. 2018;7:65
pubmed: 30139970 pmcid: 6107578 doi: 10.1038/s41389-018-0073-3
Buckley NE, Conlon SJ, Jirstrom K, Kay EW, Crawford NT, O’Grady A. et al. The ΔNp63 proteins are key allies of BRCA1 in the prevention of basal-like breast cancer. Cancer Res. 2011;71:1933–44.
pubmed: 21363924 doi: 10.1158/0008-5472.CAN-10-2717
Leong CO, Vidnovic N, DeYoung MP, Sgroi D, Ellisen LW. The p63/p73 network mediates chemosensitivity to cisplatin in a biologically defined subset of primary breast cancers. J Clin Invest. 2007;117:1370–80.
pubmed: 17446929 pmcid: 1849987 doi: 10.1172/JCI30866
Stephens PJ, Tarpey PS, Davies H, Van Loo P, Greenman C, Wedge DC. et al. The landscape of cancer genes and mutational processes in breast cancer. Nature. 2012;486:400–4.
pubmed: 22722201 pmcid: 3428862 doi: 10.1038/nature11017
Ellis MJ, Ding L, Shen D, Luo J, Suman VJ, Wallis JW. et al. Whole-genome analysis informs breast cancer response to aromatase inhibition. Nature. 2012;486:353–60.
pubmed: 22722193 pmcid: 3383766 doi: 10.1038/nature11143
Shah SP, Roth A, Goya R, Oloumi A, Ha G, Zhao Y. et al. The clonal and mutational evolution spectrum of primary triple-negative breast cancers. Nature. 2012;486:395–9.
pubmed: 22495314 doi: 10.1038/nature10933
Cancer Genome Atlas Network. Comprehensive molecular portraits of human breast tumours. Nature. 2012;490:61–70.
doi: 10.1038/nature11412
Baan B, Pardali E, ten Dijke P, van Dam H. In situ proximity ligation detection of c-Jun/AP-1 dimers reveals increased levels of c-Jun/Fra1 complexes in aggressive breast cancer cell lines in vitro and in vivo. Mol Cell Proteom. 2010;9:1982–90.
doi: 10.1074/mcp.M110.000943
Ali R, Wendt MK. The paradoxical functions of EGFR during breast cancer progression. Signal Transduct Target Ther. 2017;2:16042.
pubmed: 28435746 pmcid: 5397119 doi: 10.1038/sigtrans.2016.42
Hu L, Liang S, Chen H, Lv T, Wu J, Chen D. et al. δnp63α is a common inhibitory target in oncogenic PI3K/Ras/Her2-induced cell motility and tumor metastasis. Proc Natl Acad Sci USA. 2017;114:E3964–73.
pubmed: 28468801 doi: 10.1073/pnas.1617816114
Wagner EF, Nebreda AR. Signal integration by JNK and p38 MAPK pathways in cancer development. Nat Rev Cancer. 2009;9:537–49.
pubmed: 19629069 doi: 10.1038/nrc2694
Subramanian D, Bunjobpol W, Sabapathy K. Interplay between TAp73 protein and selected activator protein-1 (AP-1) family members promotes AP-1 target gene activation and cellular growth. J Biol Chem. 2015;290:18636–49.
pubmed: 26018080 pmcid: 4513121 doi: 10.1074/jbc.M115.636548
Kurrey NK, Jalgaonkar SP, Joglekar AV, Ghanate AD, Chaskar PD, Doiphode RY. et al. Snail and slug mediate radioresistance and chemoresistance by antagonizing p53-mediated apoptosis and acquiring a stem-like phenotype in ovarian cancer cells. Stem Cells. 2009;27:2059–68.
pubmed: 19544473 doi: 10.1002/stem.154
Bhola NE, Balko JM, Dugger TC, Kuba MG, Sanchez V, Sanders M. et al. TGF-β inhibition enhances chemotherapy action against triple-negative breast cancer. J Clin Invest. 2013;123:1348–58.
pubmed: 23391723 pmcid: 3582135 doi: 10.1172/JCI65416
Huang S, Holzel M, Knijnenburg T, Schlicker A, Roepman P, McDermott U. et al. MED12 controls the response to multiple cancer drugs through regulation of TGF-β receptor signaling. Cell. 2012;151:937–50.
pubmed: 23178117 pmcid: 3672971 doi: 10.1016/j.cell.2012.10.035
Lu D, Chen S, Tan X, Li N, Liu C, Li Z. et al. Fra-1 promotes breast cancer chemosensitivity by driving cancer stem cells from dormancy. Cancer Res. 2012;72:3451–6.
pubmed: 22586064 doi: 10.1158/0008-5472.CAN-11-2536
Xue Z, Vis DJ, Bruna A, Sustic T, van Wageningen S, Batra AS. et al. MAP3K1 and MAP2K4 mutations are associated with sensitivity to MEK inhibitors in multiple cancer models. Cell Res. 2018;28:719–29.
pubmed: 29795445 pmcid: 6028652 doi: 10.1038/s41422-018-0044-4
van Staalduinen J, Baker D, ten Dijke P, van Dam H. Epithelial–mesenchymal-transition-inducing transcription factors: new targets for tackling chemoresistance in cancer? Oncogene. 2018;37:6195–211.
pubmed: 30002444 doi: 10.1038/s41388-018-0378-x
van IJzendoorn DGP, Forghany Z, Liebelt F, Vertegaal AC, Jochemsen AG, Bovée JVMG. et al. Functional analyses of a human vascular tumor FOS variant identify a novel degradation mechanism and a link to tumorigenesis. J Biol Chem. 2017;292:21282–90.
pubmed: 29150442 pmcid: 5766951 doi: 10.1074/jbc.C117.815845

Auteurs

Anders Sundqvist (A)

Department of Medical Biochemistry and Microbiology, Science for Life Laboratory, Uppsala University, SE, 751 23, Uppsala, Sweden. anders.sundqvist@imbim.uu.se.

Eleftheria Vasilaki (E)

Department of Medical Biochemistry and Microbiology, Science for Life Laboratory, Uppsala University, SE, 751 23, Uppsala, Sweden.

Oleksandr Voytyuk (O)

Department of Medical Biochemistry and Microbiology, Science for Life Laboratory, Uppsala University, SE, 751 23, Uppsala, Sweden.

Yu Bai (Y)

Department of Medical Biochemistry and Microbiology, Science for Life Laboratory, Uppsala University, SE, 751 23, Uppsala, Sweden.

Masato Morikawa (M)

Department of Molecular Pathology, Graduate School of Medicine, The University of Tokyo, Tokyo, 113-0033, Japan.

Aristidis Moustakas (A)

Department of Medical Biochemistry and Microbiology, Science for Life Laboratory, Uppsala University, SE, 751 23, Uppsala, Sweden.

Kohei Miyazono (K)

Department of Medical Biochemistry and Microbiology, Science for Life Laboratory, Uppsala University, SE, 751 23, Uppsala, Sweden.
Department of Molecular Pathology, Graduate School of Medicine, The University of Tokyo, Tokyo, 113-0033, Japan.

Carl-Henrik Heldin (CH)

Department of Medical Biochemistry and Microbiology, Science for Life Laboratory, Uppsala University, SE, 751 23, Uppsala, Sweden.

Peter Ten Dijke (P)

Department of Medical Biochemistry and Microbiology, Science for Life Laboratory, Uppsala University, SE, 751 23, Uppsala, Sweden.
Department of Cell and Chemical Biology, Oncode Institute, Leiden University Medical Center, 2300 RC, Leiden, The Netherlands.

Hans van Dam (H)

Department of Cell and Chemical Biology, Oncode Institute, Leiden University Medical Center, 2300 RC, Leiden, The Netherlands. vdam@lumc.nl.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH